1. Product Overview

Based on the new-generation medical P34HB (polyhydroxyalkanoate) material and Ningbo Neon Lion Tech’s mature microsphere preparation platform, this product is an interventional embolization-specific PHA medical microsphere. The particle size can be precisely controlled at 20–55 μm (or customized as required), suitable for tumor interventional embolization and other endovascular therapies, achieving a dual effect of “mechanical embolization + sustained drug release”.

?

2. Key Advantages

?

Controllable Particle Size, Precise Embolization:

Standard size range: 20–55 μm (customizable within 300 nm–300 μm).

Narrow particle size distribution, SPAN ≤ 0.8, enabling accurate selection of target vessel level and predictable embolization depth.

Excellent Material Properties:

Compared with traditional materials such as PLLA, PGA, and PLGA, PHA offers superior biocompatibility and degradability.

Degradation products can be metabolized by the body and used as an energy source, reducing local acidification and inflammatory irritation.

Good toughness and mechanical strength, ensuring stable embolization and reliable long-term support.

Safety Advantages:

Low inflammatory response and low immunogenicity help reduce post-interventional complications.

Smooth in vivo degradation with minimal residue risk.

?

3. Drug Loading and Release Performance

?

Capable of loading various small-molecule chemotherapeutic drugs (e.g., DOX), forming a localized high-concentration drug reservoir at the target lesion.

By adjusting the P34HB molecular weight (50k–300k), 4HB content, and particle size range, the release profile can be precisely tuned to achieve customized regimens from short-term rapid release to long-term sustained release.

Validated in rat orthotopic liver cancer models:

Low cytotoxicity and good biosafety.

Significantly prolonged drug release duration, contributing to improved local tumor control.

DSA imaging and histological staining (H&E / Masson) confirm embolization performance and tumor suppression efficacy.

?

4. Specifications and Supply Capability

?

Recommended standard specification: P34HB matrix, 4HB content 10–13%, particle size 20–55 μm, SPAN ≤ 0.8.

Multiple molecular weight grades available: 50 kDa, 100 kDa, 150 kDa, 200 kDa, 250 kDa, 300 kDa, etc.

Microsphere production capacity: up to 10 kg per project, supporting subsequent scale-up for clinical and commercial use.

?

5. Application Scenarios

?

Transarterial chemoembolization (TACE) for liver cancer, renal cancer, and other solid tumors

Other interventional tumor therapies requiring localized sustained drug delivery

Co-development of innovative interventional embolic microsphere products with pharma or device companies